QUOTE AND NEWS
Market Intelligence Center  Jul 15  Comment 
BioMarin Pharmaceutical (BMRN) presents a trading opportunity that offers a 5.79% return in just 95 days. A covered call on BioMarin Pharmaceutical at the $55.00 level expiring on Oct. '14 offers an assigned return rate of 5.79% or 22.24%...
SeekingAlpha  Jul 15  Comment 
By SA Editor Miriam Metzinger: Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday July 14. Bullish Calls: BioMarin (NASDAQ:BMRN): "The stock is too low. It has not kept pace with the others, and it...
StreetInsider.com  Jul 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioMarin+Pharma%27s+%28BMRN%29+VIMIZIM+Receives+Approval+in+Canada/9640744.html for the full story.
Market Intelligence Center  Jun 30  Comment 
The patented options-trade picking algorithms used by MarketIntelligenceCenter.com found a trading opportunity with BioMarin Pharmaceutical (BMRN) that should provide a 7.47% return in just 110 days. Sell one Oct. '14 call at the $60.00 level for...
TheStreet.com  Jun 12  Comment 
NEW YORK (TheStreet) --  BioMarin Pharmaceutical Inc.  is rated a "buy" this morning at UBS with a $74 price target as the firm said it's an 'attractive entry point for a mid-cap holding." Must Read: Warren Buffett's 25 Favorite Growth...
TheStreet.com  Jun 9  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES Anixter was downgraded at Robert Baird to neutral from outperform. Twelve-month price target is $108. Valuation call, as the stock has outperformed the market over the past two years, Robert Baird...
TheStreet.com  Jun 9  Comment 
NEW YORK (TheStreet) -- Shares of Biomarin Pharmaceutical Inc. were upgraded to "outperform" from "neutral" at Credit Suisse which maintained its $73 price target. The firm upgraded shares due to share declines and sees potential catslysts...
Benzinga  Jun 9  Comment 
StreetInsider.com  May 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioMarin+Pharma+%28BMRN%29+Doses+First+Patient+in+Phase+3+INSPIRE+for+Pompe+Disease/9524003.html for the full story.
Market Intelligence Center  May 15  Comment 
BioMarin Pharmaceutical (BMRN) was identified by MarketIntelligenceCenter.com’s patented algorithms today after trading between $56.37 and $59.08 on Wednesday before closing at $58.44. A diagonal spread using a long position in the Jan. '15...
SeekingAlpha  May 8  Comment 
By SA Editor Miriam Metzinger: Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday May 7. Bullish Calls: BioMarin (BMRN): "BMRN is one of those that is going to be a survivor. This period is so nasty...




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki